publication venue for
- Stochastic cancer-immune coevolution: Implications for cancer incidence and immunotherapeutic efficacy.. 37:e14023-e14023. 2019
- GATA2 exosomal mRNA: A novel urine biomarker for the diagnosis of clinically significant prostate cancer.. 37:18-18. 2019
- How a Child With Cancer Moved From Vulnerability to Resilience.. 35:3169-3171. 2017
- Feasibility of wearable physical activity monitors in cancer patients (PAMCaP).. 35:6577-6577. 2017
- Quantifying the electronic medical record implementation to stabilization curve.. 35:140-140. 2017
- Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer.. 34:9040-9040. 2016
- A global genomic and small molecule inhibitor interrogation of KIT mutant melanoma to reveal underlying biology and novel molecular targets.. 33:9039-9039. 2015
- Discovery and disclosure of incidental genetic information obtained through high throughput sequencing.. 33:e17779-e17779. 2015
- Consultations between patients with breast cancer and surgeons: a pathway from patient-centered communication to reduced hopelessness.. 31:351-358. 2013
- Longitudinal relationship between inflammatory markers and patient-reported symptom severity during induction therapy for multiple myeloma.. 30:9083-9083. 2012
- Predictive value of baseline serum MIP-1 and CRP on symptom burden and tumor response to induction therapy in patients with multiple myeloma.. 30:8091-8091. 2012
- Differential gene expression in liposarcoma: Insight into pathways for dedifferentiation?. 30:10048-10048. 2012
- How to run survival-endpoint phase II trials with 25% to 40% fewer patients.. 30:2544-2544. 2012
- Inflammatory markers and symptom burden in patients with multiple myeloma undergoing autologous stem cell transplantation.. 30:9081-9081. 2012
- PTHrP(12-48) for the diagnosis of breast cancer bone metastasis.. 30:e21039-e21039. 2012
- Results of a high-throughput screen to identify compounds that modulate VHL proteostasis.. 30:369-369. 2012
- Therapeutic options in metastatic castration-resistant prostate cancer (mCRPC): A cost-effectiveness analysis.. 30:e15154-e15154. 2012
- Association of sTNF-R1 and the development of treatment-related symptoms in patients undergoing concurrent chemoradiation therapy for colorectal or esophageal cancer. 27:3041-3041. 2009
- Breath analysis as a method for breast cancer early detection. 26:1522-1522. 2008
- Racial differences in trust and lung cancer patients' perceptions of physician communication.. 24:904-909. 2006
- Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer 2023
- Analysis of real-world data (RWD) on treatment (tx) sequencing in patients with advanced non-small cell lung cancer (aNSCLC). 2019
- Investigating racial differences in treatment responses through analysis of real-world data (RWD). 2019
- Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study 2016
- A global genomic and small molecule inhibitor interrogation of KIT mutant melanoma to reveal underlying biology and novel molecular targets 2015
- Implementation and evaluation of clinical exome sequencing in childhood cancer care: The BASIC(3) study 2013
- The role of FGF signaling in VEGF-pathway targeted therapy resistance: Data from patients and model systems 2013
- Inactivation of the nuclear receptor TR3 as an important new drug target for treating RCC. 2013
- PTHrP(12-48) for the diagnosis of breast cancer bone metastasis 2012
- Fibroblast growth factor receptor 1 (FGFR1) expression and activation in clear cell renal cell carcinoma (ccRCC). 2011